Cornerstone Pharmaceuticals' CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR's Clinical Cancer …

| October 7, 2014 | 0 Comments

CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from the Phase I clinical trial evaluating CPI-613 …

View original post here:
Cornerstone Pharmaceuticals' CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR's Clinical Cancer …

Tags: , , , , , , , , ,

Category: Uncategorized

About the Author ()

Leave a Reply